Asthma
Conditions
Keywords
Biological treatment, Patient-reported outcome measures, Treatment evaluation
Brief summary
Some patients treated with biologics for severe asthma experience a craving to the next biological administration. This phenomenon has never been described before. In this study, the researchers aim to further elucidate the feeling of needing the next administration of a biologic for severe asthma.
Detailed description
Recent research by Kroes and colleagues on omalizumab levels has shown that approximately half of patients on long-term omalizumab therapy (\>4 months) experience a subjective craving for the next dose. These patients had a need (Borg scale 3-10) for the next dose of biologic before the usual periodic dose, while other patients indicated that they had no or a low need (Borg scale 0-2) for the next dose at the usual dosing moment. This so-called 'craving' has not been described in the literature before. Patients in the high-requirement group had significantly lower median omalizumab trough levels than patients in the low-requirement group. There may be a relationship between blood levels of biologics and the need for the next dose. However, data is currently only available on the variability in serum trough levels of omalizumab, but not yet on the other biologics for asthma, some of which are administered as a fixed dose and some are dosed by body weight. No assays are currently available for blood level determinations from the other biologics. Before investigating the relationship between blood levels and the need for biologics, it is important to fully map the 'craving'. Some patients who are responders to biologic therapy based on improvements in clinical outcomes still do not have good enough control of their asthma and indicate that the dosing interval is not optimal. In addition to patients that indicate a need for the next dose, there are also patients that would like a longer dosing interval. To date, dosing interval adjustments have been made based on the patient's subjective experience and the physician's clinical judgment. This study investigates how big the problem of need for the next dose is, how patients experience this need, what this need exactly entails, whether this occurs more often in patients treated for a longer period and what possible problems patients experience in the treatment with biologics against serious problems.
Interventions
None listed
Sponsors
Frisius Medisch Centrum
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Treated with a biologic for severe asthma in the Medical Centre Leeuwarden for more than 4 months
Exclusion criteria
* Not speaking Dutch
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The prevalence of craving to the next biologic administration. | 6 months | Craving will be assessed as a BORG-scale score \>2. This scale ranges from 0 (No craving at all) to 10 (Extreme craving). |
| The character of craving to the next biologic administration. | 6 months | This will be assessed by scoring the prevalence of asthma-related symptoms in patients reporting a craving. Craving will be assessed as a BORG-scale score \>2. This scale ranges from 0 (No craving at all) to 10 (Extreme craving). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Differences in craving (BORG-scale 0-10) between patients treated for more or less than 1 year. | 6 months | Craving will be assessed with a BORG-scale score. This scale ranges from 0 (No craving at all) to 10 (Extreme craving). |
| Differences in craving (BORG-scale 0-10) between patients with different biologics. | 6 months | Craving will be assessed with a BORG-scale score. This scale ranges from 0 (No craving at all) to 10 (Extreme craving). |
| Any other issues regarding the craving/administration of biologics for severe asthma, based on patient-level input from interviews. | 6 months | — |
Countries
Netherlands
Outcome results
None listed